DLBCL Clinical Trials in Guangzhou, Guangdong
8 recruitingGuangzhou, Guangdong, China
Showing 1–8 of 8 trials
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 2Phase 3
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University80 enrolled1 locationNCT07084662
Recruiting
Phase 1Phase 2
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.97 enrolled21 locationsNCT07124936
Recruiting
Phase 2
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University39 enrolled11 locationsNCT06647940
Recruiting
Phase 2
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
DLBCL
Sun Yat-sen University38 enrolled1 locationNCT06569485
Recruiting
Phase 2
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma
DLBCL Germinal Center B-Cell Type
Li Zhiming50 enrolled6 locationsNCT05422066